quickweightloss

Source: AlphaRx Inc. MARKHAM, Ontario, March 8, 2006 (PRIMEZONE) -- AlphaRx Inc. (OTCBB:ALRX), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to announce that its joint venture company, Alpha AP Inc., located in Hong Kong, has received marketing approval for the sale of Flexogan Ultra in Asia. It is anticipated that Flexogan and Flexogan Ultra will be just two of the many innovative pharmaceutical products which will be licensed to Alpha AP to be marketed by Alpha AP under the AP brand in Asia. which is a scaled-down version of Indaflex(tm), also received marketing approval for the sale of Flexogan(tm) in Hong Kong.

manufacture and market the products in China, Hong Kong, Korea and Japan. Under the terms of the Joint Venture agreement, Advance Pharmaceutical Co. Ltd. ("APC") will fund the Joint Venture, With AlphaRx's enhanced proprietary nano delivery system, the Company believes Flexogan's effectiveness will be significantly greater when compared to other over-the-counter topical preparations available on the market. In addition to the entry of Flexogan into the Asian market, the Company recently announced that Flexogan Ultra, which is a scaled-down version of Indaflex(tm), also received marketing approval for the sale of Flexogan Ultra in Asia. Flexogan Ultra contains 1% Indomethacin which is used to relieve the pain, tenderness, inflammation (swelling), and stiffness caused by gout, arthritis, and other inflammatory conditions. Flexogan is only the second pharmaceutical product, after Flexogan Ultra, allowed by the health authority to make a "Nano Formulation" marketing claim. The "Nano Formulation" claim will play a significant part in the marketing of Flexogan in Asia as it will provide a significant differentiator from other products available in the Asian market. It is anticipated that Flexogan and Flexogan Ultra will be just two of the many innovative pharmaceutical products which will be licensed joint relief to Alpha AP to be marketed in Asia.

Flexogan is a deep penetrating topical cream that provides temporary relief from pain associated with joints, muscles and minor arthritis. Flexogan will be AlphaRx's first over-the-counter product to be marketed in Asia. About Alpha AP Inc. ("AAP"), is headquartered in Hong Kong.

Under the terms of the licensing agreement, as amended, AlphaRx will provide 10 products to the Joint Venture, AlphaRx will receive a 5% royalty from the Joint Venture's gross sales. AlphaRx will also receive a one time licensing fee of US$11M from the Joint Venture, contingent upon completion of its Hong Kong public stock offering. Forward-Looking Statements: This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company. Keywords: PHARMACEUTICALS, HEALTH Other News Releases from AlphaRx Inc.

Related Industry: Healthcare News © PrimeNewswire, Inc. All Rights Reserved. Advance Shipment Notice (ASN) transaction enables the sender to relate the passive RFID tag ID at various levels of detail to the contents and configuration of a shipment. The tag ID is written to the tag in binary format. However, within the ASN, you must provide the ID of every RFID tag in a shipment and must represent this passive tag ID in a hexadecimal format. Typically, the hexadecimal format is the format used by passive RFID software in printers and readers thus the binary to hexadecimal translation process should be done automatically by the software.

For more detailed information, please consult the supplier guide at:.